In this episode, Veronica Breckenridge, Managing Partner of First Bight Ventures, challenges the prevailing myth that industrial biotech is uninvestable by advocating for a model rooted in capital efficiency and strategic realism. She argues that while these businesses are CapEx-heavy, they can deliver strong equity returns if founders utilize project finance and non-dilutive capital rather than relying solely on dilutive equity. Breckenridge’s investment thesis prioritizes technologies that achieve cost parity, avoid product-market risk, and involve early strategic buyers to define specifications for eventual M&A. Ultimately, she emphasizes that successful companies in this space must move away from “SaaS-style” thinking and instead focus on disciplined manufacturing, avoiding expensive errors, and securing government or debt funding to scale without the need for “unicorn” valuations.
Investment Climate Podcast: Veronica Breckenridge of First Bight Ventures Shares How to Get Funded in 2026
ByGrégory Maubon
Jan 6, 2026
By Grégory Maubon
Leading Innovation ++ on the Field ++ with a Purpose => I used AI in cultivated meat industry to optimize bioreactor design and to dramatically improve the efficiency and quality of production. I developed high quality 3D imagery process in a biotechnological startup to disrupt the drug discovery methods.